REPL logo

Replimune Group, Inc.


REPL: Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.


Show REPL Financials

Consumer Interest
SEC Filings

Recent trades of REPL by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by REPL's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Oncolytic virus strain Oct. 18, 2022
  • Patent Title: Modified oncolytic virus Aug. 30, 2022
  • Patent Title: Engineered virus Mar. 16, 2021
  • Patent Title: Oncolytic virus strain Feb. 25, 2020
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of REPL in WallStreetBets Daily Discussion


Recent insights relating to REPL

CNBC Recommendations

Recent picks made for REPL stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in REPL

Corporate Flights

Flights by private jets registered to REPL